Scholars Central

Review articlePublished 28 Feb 2023

Suspension vs Conventional Pump Therapy for Hypoglycemic Unaware Patients with Type 1 Diabetes

Authors: Tim Jones

Journal of Diabetes & Metabolism

Volume 14 · Issue 2 · Pages 1–3

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In patients with type 1 diabetes who lack awareness of hypoglycaemia, the objective was to compare the cost-effectiveness of sensor-augmented insulin pump therapy with "Low Glucose Suspend" (LGS) functionality to standard pump therapy with self-monitoring of blood glucose. Methods: The net costs and effectiveness of the two treatment options were calculated and expressed as an incremental cost-effectiveness ratio (ICER) in an economic evaluation based on a clinical trial. The rate of severe hypoglycaemia in each LGS study arm was the clinical outcome of interest for the evaluation. Personal satisfaction utility scores were determined utilizing the three-level EuroQol five-layered survey. Costs associated with resource use were estimated using public data. Results: At six months, compared to standard pump therapy, the use of sensor-augmented insulin pump therapy with LGS significantly reduced the incidence of severe hypoglycaemia (incident rate difference 1.85 [0.17–3.53]); P = 0.037). The ICER per severe hypoglycaemic event avoided was $18,257 for all patients in a primary randomized study and $14,944 for patients over the age of 12. The ICERs were $17,602 and $14,289, respectively, when all major medical resource costs (like hospital admissions) were taken into account. For patients over the age of 12, the cost per quality-adjusted life-year gained over the course of the six months was $40,803. Conclusions: In type 1 diabetes patients who are unaware of their hypoglycaemia, sensor-augmented insulin pump therapy with LGS may be considered a cost-effective alternative to standard pump therapy with selfmonitoring of blood glucose. This is based on the Australian experience evaluating new interventions across a wide range of therapeutic areas. Keywords Cost-effectiveness; Hypoglycaemia; Insulin pump therapy; Type 1 diabetes

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Diabetes & Metabolism.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Diabetes & Metabolism
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Tim Jones”